VM-RHE-002
An oral therapy in development for chronic pain associated with osteoarthritis in patients with limited treatment options.
VM-PAIN-004
An oral repurposed therapeutic in late-stage development for complex regional pain syndrome.
VM-PAIN-003
A novel small-molecule program being developed for severe neuropathic pain, including trigeminal neuralgia.
VM-NEU-003
A selective CNS therapy under development for individuals with treatment-resistant epilepsies.
VM-PSY-006
A cannabinoid-based investigational therapy being developed for post-traumatic stress disorder.
VM-PSY-005
An oral small-molecule candidate in development for opioid use disorder.
VM-NEU-002
A novel CNS therapeutic candidate being developed for early Alzheimer’s disease.
VM-PAIN-002
An investigational therapy aimed at improving pain control following surgical procedures.
VM-PSY-004
A next-generation small molecule in development for adults trying to reduce or stop tobacco use.
VM-PUL-001
A first-in-class monoclonal antibody in Phase 2 development for Acute Respiratory Distress Syndrome, aiming to address a critical unmet need in a condition with no approved therapies.